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rotic cardiovascular disease (ASCVD) [1e3]. If left untreated, the
relative risk of premature coronary artery disease is signiﬁcantly
higher in heterozygous patients than unaffected individuals, with
most untreated homozygotes developing ASCVD before the age of
20 and generally not surviving past 30 years [2e5]. Although early
detection and treatment with statins and other LDL-C lowering
therapies can improve survival, FH remains widely underdiagnosed
and undertreated [1], thereby representing a major global public
health challenge.
Whilst the prevalence of heterozygous FH has been traditionally
estimated as ~1:500, contemporary data suggest an overall fre-
quency of ~1:200e300, implying that >30million individuals could
be affected worldwide [1,3,4,6]. Furthermore, the burden of the
disease is even higher in subpopulations with gene founder effects
or within communities where consanguineous marriages are
common [7]. Available information suggests that <5% of those
affected are diagnosed, with higher detection rates reported among
countries with formal screening programmes [1]. Similarly, ho-
mozygous FH is now considered to have a higher prevalence of
1:160,000e300,000 (calculations based on suggested heterozygous
frequency of ~1:200e300) instead of the historical ﬁgure of
1:1,000,000 [1,2,8]. Additionally, FH is either insufﬁciently treated
or treated late and, even with current best therapies (high-dose
statins and cholesterol absorption inhibitors), only ~20% of in-
dividuals attain guideline-recommended LDL-C goals [1,9,10].
These factors are also compounded by a general lack of public
health policies aimed speciﬁcally at FH, lack of uniformity among
various initiatives for remediating the gaps in care, and the absence
of a speciﬁc WHO “International Classiﬁcation of Diseases” code for
FH itself (currently included together with other disorders within
the heading “pure hypercholesterolaemias” [ICD-10 code E78.0])
[11]. For example, the identiﬁcation of new FH subjects is mainly
based on clinical criteria in most regions, whereas in others genetic
conﬁrmation of the diagnosis in index cases and relatives according
to a cascade testing strategy is utilised [1]; additionally, although a
cascade screening strategy has been found to be cost-effective [12]
and may promote risk reduction by early initiation of therapy, only
a few regions/nations have implemented it widely (Suppl. material
1).To overcome the existing gaps in care and reduce the prevent-
able global burden of disease arising from FH, major efforts are
needed to institute early detection and effective treatment. Central
to these efforts is increasing awareness, dissemination of infor-
mation and promotion of education among healthcare providers,
policy makers and patients. The generation of high-quality and
reliable data on current clinical practice and policies and their
consequences on health outcomes may help support decision-
making by demonstrating the gaps in existing levels of healthcare
and geographical inequalities. Collaboration and partnership be-
tween healthcare professionals, patient organizations, healthcare
providers and policy makers are essential to develop a scalable and
sustainable best standard of care of patients and families with FH.
FH has no geographical boundaries, and each country will face its
speciﬁc challenges in delivering the best care for FH. Therefore,
establishing priorities, identifying short and long-term goals, and
implementing and evaluating models of care are essential for
shaping and developing the most effective health policy on FH.
Different approaches may be required and availing all resources
should be explored in order to achieve these objectives (Fig. 1).
To ﬁll the current gap in public health initiatives on FH, both
professional and patients organizations have initiated programmes
to address the aforementioned gaps in care (Suppl. material 1),
occasionally at an international level, but more frequently at na-
tional or regional levels, including screening programmes, educa-
tional and awareness activities, consensus statements or
accessibility to therapies. The current challenges and need for
large-scale information to support the best evidence-based care
and policies suggest, however, that the time is ripe for an inter-
national call-to-action that integrates efforts across the world to
tackle the health burden and gaps in care of FH.
In this context, the European Atherosclerosis Society (EAS) FH
Studies Collaboration (FHSC) has been launched as an ambitious
global initiative that, through a consortium of major FH registries
worldwide, aims to generate large-scale robust data on how FH is
detected and managed and the clinical implications thereof. The
ultimate aims are to disseminate this information in order to
empower themedical, global and lay community to seek changes in
their respective countries or organizations to improve the care of
patients and families with FH (Suppl. material 2). A number of
leaders in the ﬁeld have agreed to contribute to this international
initiative (Suppl. material 3) resulting in a global network that will
ultimately generate novel data to inform future guidelines on FH
management. Under the auspices of the EAS FHSC, a recent “patient
advocacy group” meeting brought together patients' organizations
representatives and clinicians (Suppl. material 4). The key aims and
objectives identiﬁed were raising awareness and education (with a
special focus on primary care providers), improving health policies,
establishing networks among different regions including patients
Fig. 1. Familial hypercholesterolaemia (FH) poses important global public health concerns, being globally underdiagnosed and undertreated. Key aspects to be covered to face the
FH burden include early diagnosis of the disease and screening strategies, generation of large-scale reliable data (e.g. by means of registries) and encouraging research on FH, raising
awareness and education within healthcare professionals, policy makers, patients and families, development of policies aimed speciﬁcally to FH, and the establishment of early and
effective treatment (including facilitating access to therapies, also to novel drugs). These actions should be led by professional bodies within their scope of action in partnership with
patients' organizations and health authorities. See Suppl. material 1. CV: cardiovascular. EAS: European Atherosclerosis Society. FH: familial hypercholesterolaemia. FHSC: FH Studies
Collaboration. IAS: International Atherosclerosis Society.and professional organizations, and accessibility to treatments,
among others.
The FH awareness week/day (24th September) intends to
emphasize the health burden andmajor challenges in care posed by
FH by undertaking different awareness-raising activities to make
healthcare providers, policy makers, and patients and families
more aware of the need to take action to ﬁght the problem of FH.
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